F8 and hemophilia A: In addition to this, a second study demonstrated that when administered subcutaneously, fitusiran showed potent, dose-dependent, and durable reductions in AT levels in wild-type mice, mice with hemophilia A, and nonhuman primates with anti-FVIII inhibitors, resulting in improved thrombin generation [44].